🎄 Click here for our
Christmas ordering and delivery dates
Totiva

Retatrutide Half-Life: About 6 to 7 Days, and What That Means

Retatrutide's half-life is reported as roughly 6 to 7 days. Here is where that figure comes from, how long it stays in your body, and why it is not available in the UK.

Written by

MPharm, Independent Prescriber (IP)

Reviewed by

Chris ArmstrongMedically reviewed

MPharm

Updated 6 min read

Key Takeaways

Retatrutide's half-life is about 6 to 7 days, so it was given weekly in trials and takes roughly 5 weeks to clear. It has no UK licence. Do not buy it online.

The half-life of retatrutide is reported as about 6 to 7 days. That means the amount in your blood falls by half roughly once a week, which is why trials gave it as a once-weekly injection. Retatrutide is still an experimental medicine. It has no UK licence, so everything below comes from clinical trial data, not from treatment advice.

Where the 6 to 7 day figure comes from#

A half-life is the time it takes for the level of a drug in your blood to drop by half. A longer half-life means you can inject less often and keep levels steadier between doses.

The figure for retatrutide comes from early (Phase 1) studies in volunteers, then supported by the larger Phase 2 obesity trial. Early work put it at around 6 days, and later trial summaries often round it to about 7. Both numbers describe the same thing. Half-life is an average across many people, and it varies a little between individuals.

No trial has been designed to give one exact number for everyone. If you see "7 days" quoted, treat it as a good estimate, not a fixed fact.

How it compares with Wegovy and Mounjaro#

MedicineActive ingredientApprox. half-lifeDosing
Retatrutide (trials only)Retatrutide6 to 7 daysOnce a week
WegovySemaglutideAbout 7 daysOnce a week
MounjaroTirzepatideAbout 5 daysOnce a week

All three are long-acting enough for weekly use. Retatrutide sits close to semaglutide and a little above tirzepatide. Retatrutide also acts on three hormone receptors (GLP-1, GIP and glucagon), where Wegovy acts on one and Mounjaro on two. Our guide on how retatrutide works covers that in more detail.

Check your BMI

Not sure where you stand? Work out your BMI in seconds and see whether weight loss treatment could be an option.

Check my BMI

What a 6 to 7 day half-life means in practice#

A drug is usually treated as mostly gone after about 5 half-lives. For retatrutide that is roughly 30 to 35 days. This timeline affects three things.

  • Building up: Levels take around 4 to 5 weeks to settle at a steady level on a fixed dose.
  • Clearing out: After your last injection, the drug takes about 5 weeks to leave your body. Appetite effects tend to fade gradually, not overnight.
  • Side effects: If a dose upsets your stomach, the drug cannot be "switched off". Nausea or diarrhoea can last days, because the medicine is still active.

The same logic explains missed doses. Because levels fall slowly, one late injection does not drop you to zero. Outside a trial there is no approved advice for retatrutide, and trial teams follow their own protocol. For comparison, the licensed pens have set rules: Mounjaro can usually be taken up to 4 days late, and Wegovy up to 5 days late.

A long half-life also matters for anything involving your stomach or surgery. GLP-1 medicines slow how fast the stomach empties, and that effect lingers for weeks after the last dose. Anaesthetists ask about this before an operation. How retatrutide affects the contraceptive pill has not been established.

What the trials have shown so far#

The main published data come from a Phase 2 trial in the New England Journal of Medicine. It included 338 adults with obesity, or overweight plus a weight-related condition. They were given weekly injections for 48 weeks at doses of 1mg, 4mg, 8mg or 12mg, or placebo (a dummy injection).

At 48 weeks, people on the 12mg dose lost an average of 24.2% of their body weight. People on placebo lost about 2.1%. Dose increases in trials were made every 4 weeks, starting from a low dose, to ease stomach side effects.

The most common side effects were nausea, diarrhoea, vomiting and constipation. They were mostly mild to moderate, appeared during dose increases, and were more common at higher doses. Heart rate also went up in the early months. Some people reported unusual skin sensations, and more people stopped treatment at the higher doses.

Phase 3 trials are the large final stage before a licence application, and this page relies on the published Phase 2 data described above. Phase 2 gives a strong signal, but not the full picture.

Weight loss treatments we prescribe

Mounjaro

Lose 22.5% body weight on average

PriceFrom £136.88/mo
Explore Mounjaro
Wegovy

Lose 20.7% body weight on average

PriceFrom £92.88/mo
Explore Wegovy
Wegovy Tablets

Lose 16.6% body weight on average

PriceFrom £98.00/mo
Explore Wegovy Tablets
Foundayo

Lose 12.4% body weight on average

PriceFrom £85.88/mo
Explore Foundayo

What we do not know yet#

  • Long-term safety beyond the trial periods
  • The best dose and escalation plan for different people
  • How it interacts with other medicines
  • How it compares head to head with Mounjaro in everyday use
  • What it will cost, and whether the NHS will fund it

We will update this page when Phase 3 results and any regulatory decisions are published. Last checked: November 2026.

Retatrutide sold online in the UK#

Retatrutide has no marketing authorisation from the MHRA, the UK medicines regulator. A licence needs full trial evidence on safety, quality and benefit, and the MHRA has not approved it. It is not available on the NHS.

You may still see vials sold online as "research peptides" or "not for human consumption". This is how sellers try to avoid medicines law. Because retatrutide has no authorisation, it cannot be lawfully sold or supplied to the public for human use, and a GPhC-registered pharmacy cannot legally supply it.

The risks are real, and the long half-life makes them worse:

  • You cannot know what is in the vial. Purity, strength and sterility are unchecked, and the MHRA has seized illicit weight loss products.
  • There is no tested dose for home use. Trial doses were built up slowly under medical supervision.
  • A mistake lasts. With 5 weeks to clear, an overdose or a reaction cannot be quickly reversed.

If you have already used it, tell a pharmacist or your GP. They will not judge you. Suspected side effects can be reported through the MHRA Yellow Card scheme. For more, see where to buy retatrutide in the UK.

What you can use now, and how to find trials#

Licensed options exist. Mounjaro (tirzepatide) and Wegovy (semaglutide) are both weekly injections with full MHRA approval. On the NHS, Mounjaro is being rolled out in phases, generally for adults with a BMI of 35 or more plus at least one weight-related condition. Privately, you can get them through a GP or a GPhC-registered online pharmacy after a clinical assessment. Totiva offers weight loss treatment this way, and suitability is always checked by a UK clinician.

If you want to try retatrutide itself, the safe route is a clinical trial. You can search NIHR Be Part of Research and ClinicalTrials.gov. Trials have strict entry rules on BMI, health conditions and other medicines, and not everyone will qualify.

If you are comparing the options, our retatrutide vs Mounjaro vs Wegovy comparison lays them out side by side.

Mounjaro

Is Mounjaro right for you?

From£136.88a month

Answer a few questions and a pharmacist will review whether treatment is suitable. You only pay if you're approved.

  • GPhC-registered pharmacists
  • Free online consultation
  • Discreet, tracked delivery

Frequently asked questions

Medical Information: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any treatment.

Written by

Callum Armstrong

Callum Armstrong

MPharm Independent Prescriber (IP)

Superintendent Pharmacist & Independent Prescriber

Callum Armstrong is a GPhC-registered pharmacist and independent prescriber with over 8 years of clinical experience. Specialising in weight management, hair loss, erectile dysfunction, and dermatology, he combines clinical expertise with a background in digital health and pharmacy software to deliver evidence-based, patient-centred care. As Superintendent Pharmacist at Totiva Health, Callum oversees the clinical governance and quality standards that underpin every service.

Credentials:MPharmIndependent Prescriber (IP)Weight LossHair LossErectile DysfunctionDermatologyDigital Health & Pharmacy Software

Medically reviewed by

Chris Armstrong

Responsible Pharmacist

Chris Armstrong is a GPhC-registered pharmacist with over 40 years of experience in community pharmacy. Having founded and operated his own pharmacy business for four decades, Chris brings an unrivalled depth of knowledge in dispensing practice, pharmacy operations, and patient-centred service delivery. His career on the front line of community pharmacy makes him a trusted voice on medication management, regulatory compliance, and the practical realities of healthcare access.

Credentials:MPharmPharmacy DispensingPharmacy OperationsCommunity Pharmacy Management